Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Hubei Key Laboratory of Molecular Imaging, Wuhan, 430022, China.
Abdom Radiol (NY). 2022 Jan;47(1):443-451. doi: 10.1007/s00261-021-03326-y. Epub 2021 Oct 29.
The purpose of this study was to evaluate the therapeutic efficacy and safety of endovascular treatment for patients with visceral and renal artery aneurysms (VRAAs). Twelve years of experience with interventional procedures and treatment options in our center were also worth discussing.
From January 2009 to December 2020, clinical data of 159 consecutive patients with VRAAs were retrospectively analyzed. Patients' demographic and clinical data were recorded, and the safety and efficacy of endovascular therapy were evaluated. In addition, interventional procedures were also described.
A total of 159 patients underwent angiography, and 154 patients were successfully treated with endovascular therapy, with a technical success rate of 96.9%. Of the 154 patients with successful endovascular therapy, 3 patients died within 30 days of treatment, with a 30-day mortality rate of 1.9%, and the remaining patients were clinically successful, with a clinical success rate of 98.1%. Fifty-seven patients underwent emergency interventional treatment due to ruptured aneurysm. There were statistically significant differences in hemoglobin before and after emergency treatment (78.5 ± 22.0 g/dL vs. 93.8 ± 15.0 g/dL, P = 0.00). No other serious complications occurred except death in 3 patients.
Endovascular treatment of VRRAs is safe and effective and can significantly improve the symptoms of patients, especially those with ruptured aneurysms.
本研究旨在评估血管内治疗内脏和肾动脉动脉瘤（VRAAs）患者的疗效和安全性。还值得讨论我们中心 12 年来的介入治疗经验和治疗选择。
回顾性分析 2009 年 1 月至 2020 年 12 月期间 159 例 VRAAs 患者的临床资料。记录患者的人口统计学和临床数据，并评估血管内治疗的安全性和疗效。此外，还描述了介入手术过程。
共 159 例患者接受了血管造影检查，其中 154 例患者成功接受了血管内治疗，技术成功率为 96.9%。在成功接受血管内治疗的 154 例患者中，3 例患者在治疗后 30 天内死亡，30 天死亡率为 1.9%，其余患者均临床成功，临床成功率为 98.1%。57 例患者因破裂性动脉瘤而行紧急介入治疗。紧急治疗前后血红蛋白差异有统计学意义（78.5±22.0 g/dL 比 93.8±15.0 g/dL，P=0.00）。除 3 例死亡外，无其他严重并发症发生。
血管内治疗 VRRAs 安全有效，可明显改善患者症状，尤其是破裂性动脉瘤患者。
